Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient

American Journal of Transplantation

Volumn 15, Issue 3, 2015, Pages 827-832

  Macesic, N ^a   Langsford, D ^a   Nicholls, K ^a   Hughes, P ^a   Gottlieb, D J ^b   Clancy, L ^b   Blyth, E ^b,c   Micklethwaite, K ^b   Withers, B ^b   Majumdar, S ^a   Fleming, S ^a   Sasadeusz, Joseph ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

antibiotic drug resistance; antibiotic: antiviral ganciclovir valganciclovir; clinical research practice; infection and infectious agents; infectious disease; kidney transplantation nephrology; viral: Cytomegalovirus (CMV)

Indexed keywords

ARTESUNATE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CREATININE; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP65; FIBRIN; GAMMA INTERFERON; GANCICLOVIR; HAPTOGLOBIN; HEMOGLOBIN; INTERLEUKIN 2; LACTATE DEHYDROGENASE; LEFLUNOMIDE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA; ANTIVIRUS AGENT;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADOPTIVE IMMUNOTHERAPY; ADULT; ANTIGEN PRESENTING CELL; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INCLUSION; CELL THERAPY; COLITIS; CRYOPRESERVATION; CYSTECTOMY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; CYTOTOXICITY ASSAY; DIALYSIS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOTHELIUM CELL; FEASIBILITY STUDY; FEVER; GASTROINTESTINAL SYMPTOM; GLOMERULOPATHY; GRAFT RECIPIENT; HELPER CELL; HEMATOPOIETIC STEM CELL; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTERFERON PRODUCTION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEDICAL HISTORY; MIDDLE AGED; NEPHRECTOMY; PLASMAPHERESIS; PRIORITY JOURNAL; SALVAGE THERAPY; T CELL CULTURE; T LYMPHOCYTE; TARGET CELL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSITIONAL CELL CARCINOMA; URINE VOLUME; VIRUS INFECTION; VIRUS LOAD; CYTOLOGY; CYTOMEGALOVIRUS INFECTIONS;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 84923281820     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13023     Document Type: Article

References (12)

1. Le Page AK, Jager MM, Iwasenko JM, Scott GM, Alain S, Rawlinson WD,. Clinical aspects of Cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013; 56: 1018-1029.
2. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369: 1227-1236.
3. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
4. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121: 5113-5123.
5. Uhlin M, Gertow J, Uzunel M, et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012; 55: 1064-1073.
6. Brestrich G, Zwinger S, Fischer A, et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009; 9: 1679-1684.
7. Blyth E, Clancy L, Simms R, et al. Donor-derived CMV specific T-cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013; 121: 3745-3758.
8. Clancy LE, Blyth E, Simms RM, et al. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution. Biol Blood Marrow Transplant 2013; 19: 725-734.
9. Eiz-Vesper BB, Maecker-Kolhoff BB, Blasczyk RR,. Adoptive T-cell immunotherapy from third-party donors: Characterization of donors and set up of a T-cell donor registry. Front Immunol 2011; 3: 410.
10. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131.
11. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus specific T lymphocytes. Nat Med 1996; 2: 551-555.
12. Egli A, Humar A, Kumar D,. State-of-the-art monitoring of Cytomegalovirus-specific cell-mediated immunity after organ transplant: A primer for the clinician. Clin Infect Dis 2012; 55: 1678-1689.